Invitrogen beats Street EPS

Research tool supplier IVGN reported third quarter EPS of $0.57, beating the Street consensus estimate by $0.05 and up 24% from $0.46 for the same period last year. Revenues for the quarter came in at $196.9 million, up 21% from $162.6 million in the third quarter of 2002. The growth was driven by a 28% increase in sales of its cell culture products. Also, sales of its molecular biology products increased 17%, largely because of product offerings obtained through IVGN's 2002 and 2003 acquisitions of InforMax and Molecular Probes, respectively, and its 2003 acquisition of assets from PanVera (Madison, Wisc.). ...